Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.

Literature DB >> 29699936

IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.

Abstract

IL-6 is a critical cytokine in acute phase response and involved in the pathogenesis of several chronic inflammatory diseases including cancer. Studies have highlighted that levels of IL-6 and its family members can be useful for diagnosis, prognosis of relapse-free survival and recurrence. IL-6 family cytokines have been identified as cancer biomarkers through screening of inflammatory mediators in different fluids including saliva, serum, and bronchoalveolar lavage fluid (BALF). IL-6 can be modulated by chemopreventive drugs, small molecules, monoclonal antibodies and immune checkpoint inhibitors. Unveiling the different sources of IL-6, the interaction between IL-6 and its cellular targets, the IL-6-dependent tumor resistance mechanisms, and the identification of novel regulators of IL-6 are some of the highly complex topics included in this review and their understanding could aid cancer biomarkers and therapy development. Published by Elsevier Ltd.

Entities: CellLine Chemical Disease Gene Mutation Species

Keywords: Cancer biomarker; Cytokine; IL-6; IL-6 family; Immunoprevention

Mesh：

Substances：

Year: 2018 PMID： 29699936 PMCID： PMC6085880 DOI： 10.1016/j.cytogfr.2018.04.004

Source DB: PubMed Journal: Cytokine Growth Factor Rev ISSN： 1359-6101 Impact factor: 7.638

82 in total

1. Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma.

Authors: Ajai Chari; Hadass Pri-Chen; Sundar Jagannath
Journal: Clin Lymphoma Myeloma Leuk Date: 2013-01-10

Review 2. The two faces of IL-6 in the tumor microenvironment.

Authors: Daniel T Fisher; Michelle M Appenheimer; Sharon S Evans
Journal: Semin Immunol Date: 2014-03-03 Impact factor: 11.130

3. Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol.

Authors: Nese Unver; Oliver Delgado; Kirubel Zeleke; Amber Cumpian; Ximing Tang; Mauricio S Caetano; Hong Wang; Hiroyuki Katayama; Hua Yu; Eva Szabo; Ignacio I Wistuba; Seyed Javad Moghaddam; Samir M Hanash; Edwin J Ostrin
Journal: Int J Cancer Date: 2017-12-23 Impact factor: 7.396

4. BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.

Authors: Valerae O Lewis; Eswaran Devarajan; Marina Cardó-Vila; Dafydd G Thomas; Eugenie S Kleinerman; Serena Marchiò; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal: Proc Natl Acad Sci U S A Date: 2017-07-11 Impact factor: 11.205

Review 5. Interleukin-6 signaling pathway in targeted therapy for cancer.

Authors: Yuqi Guo; Feng Xu; TianJian Lu; Zhenfeng Duan; Zhan Zhang
Journal: Cancer Treat Rev Date: 2012-05-29 Impact factor: 12.111

6. Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression.

Authors: Chao-Qun Wang; Hao-Ting Sun; Xiao-Mei Gao; Ning Ren; Yuan-Yuan Sheng; Zheng Wang; Yan Zheng; Jin-Wang Wei; Kai-Li Zhang; Xin-Xin Yu; Yin Zhu; Qin Luo; Lu-Yu Yang; Qiong-Zhu Dong; Lun-Xiu Qin
Journal: Am J Cancer Res Date: 2016-09-01 Impact factor: 6.166

7. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors: Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal: Cancer Cell Date: 2009-02-03 Impact factor: 31.743

8. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors: Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal: Science Date: 2007-07-06 Impact factor: 47.728

9. Interleukin-6 suppression reduces tumour self-seeding by circulating tumour cells in a human osteosarcoma nude mouse model.

Authors: Yinglong Zhang; Qiong Ma; Tao Liu; Guofeng Guan; Kailiang Zhang; Jiayan Chen; Nan Jia; Shiju Yan; Guanyin Chen; Shiluan Liu; Kuo Jiang; Yao Lu; Yanhua Wen; Haien Zhao; Yong Zhou; Qingyu Fan; Xiuchun Qiu
Journal: Oncotarget Date: 2016-01-05

10. Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling.

Authors: D J Junk; B L Bryson; J M Smigiel; N Parameswaran; C A Bartel; M W Jackson
Journal: Oncogene Date: 2017-03-13 Impact factor: 8.756

47 in total

1. Innate immune activation and depressive and anxious symptoms across the peripartum: An exploratory study.

Authors: Lauren M Osborne; Gayane Yenokyan; Kezhen Fei; Thomas Kraus; Thomas Moran; Catherine Monk; Rhoda Sperling
Journal: Psychoneuroendocrinology Date: 2018-08-31 Impact factor: 4.905

Review 2. The role of interleukin-6 in glucose homeostasis and lipid metabolism.

Authors: Louise Lang Lehrskov; Regitse Højgaard Christensen
Journal: Semin Immunopathol Date: 2019-05-17 Impact factor: 9.623

3. The Effect of Zinc and Melatonin Administration on Lipid Peroxidation, IL-6 Levels, and Element Metabolism in DMBA-Induced Breast Cancer in Rats.

Authors: Elif Gulbahce-Mutlu; Saltuk Bugra Baltaci; Esma Menevse; Rasim Mogulkoc; Abdulkerim Kasim Baltaci
Journal: Biol Trace Elem Res Date: 2020-06-22 Impact factor: 3.738

4. Effects of cerebral artery thrombectomy on efficacy, safety, cognitive function and peripheral blood Aβ, IL-6 and TNF-α levels in patients with acute cerebral infarction.

Authors: Chun Chen; Yiyi Zhu; Yan Chen; Zengjun Wang; Liandong Zhao
Journal: Am J Transl Res Date: 2021-12-15 Impact factor: 4.060

5. The role of microRNA-30c in targeting interleukin 6, as an inflammatory cytokine, in the mesenchymal stem cell: a therapeutic approach in colorectal cancer.

Authors: Mohamad Mahjoor; Hamed Afkhami; Mohammad Najafi; Atieh Nasr; Samaneh Khorrami
Journal: J Cancer Res Clin Oncol Date: 2022-07-25 Impact factor: 4.322

6. The role of uropathogenic Escherichia coli adhesive molecules in inflammatory response- comparative study on immunocompetent hosts and kidney recipients.

Authors: Bartosz Wojciuk; Karolina Majewska; Bartłomiej Grygorcewicz; Żaneta Krukowska; Ewa Kwiatkowska; Kazimierz Ciechanowski; Barbara Dołęgowska
Journal: PLoS One Date: 2022-05-23 Impact factor: 3.752

Review 7. Organoids as Complex In Vitro Models for Studying Radiation-Induced Cell Recruitment.

Authors: Benjamin C Hacker; Marjan Rafat
Journal: Cell Mol Bioeng Date: 2020-06-15 Impact factor: 2.321

8. Milk‑derived hexapeptide PGPIPN prevents and attenuates acute alcoholic liver injury in mice by reducing endoplasmic reticulum stress.

Authors: Qia Xu; Hao Xi; Xi Chen; Yin Xu; Peng Wang; Jingwen Li; Wenmei Wei; Fang Gu; Yide Qin
Journal: Int J Mol Med Date: 2020-06-16 Impact factor: 4.101

9. Simultaneous Inhibition of Three Major Cytokines and Its Therapeutic Effects: A Peptide-Based Novel Therapy against Endotoxemia in Mice.

Authors: Hung-Jen Shih; Chao-Yuan Chang; Milton Chiang; Van Long Le; Hao-Jen Hsu; Chun-Jen Huang
Journal: J Pers Med Date: 2021-05-20

10. lncRNA MIAT/HMGB1 Axis Is Involved in Cisplatin Resistance via Regulating IL6-Mediated Activation of the JAK2/STAT3 Pathway in Nasopharyngeal Carcinoma.

Authors: Xuewei Zhu; Li Liu; Yang Wang; Jianan Cong; Zhang Lin; Yongsen Wang; Qi Liu; Leiming Wang; Ben Yang; Tao Li
Journal: Front Oncol Date: 2021-05-20 Impact factor: 6.244